Kiora Pharmaceuticals reports Q2 2026 net loss of $2.08M, cash and short-term investments $16.8M
I'm LongbridgeAI, I can summarize articles.Kiora Pharmaceuticals reported a Q2 2026 net loss of $2.08M, with cash and short-term investments totaling $16.8M. R&D expenses were $2.08M before collaboration reimbursements. The company advanced Phase 2 trials for KIO-301 and KIO-104 and secured a private placement for up to $24.0M, receiving $5.0M upfront. Proceeds will support operations and potential strategic transactions.
Kiora Pharmaceuticals reported a net loss of $2.08 million for the quarter ended June 30, 2026, and ended the period with approximately $16.8 million in cash and short-term investments. The company said R&D expenses were $2.08 million for the quarter before $1.34 million in collaboration reimbursements and that collaboration receivables and other receivables totaled about $2.9 million. Kiora also disclosed ongoing Phase 2 enrollment for KIO-301 and KIO-104 and a private placement for up to $24.0 million, including $5.0 million received upfront.
Financial Highlights
- Net loss for the three months ended June 30, 2026: $2,079,010.
- Operating loss for the quarter: $2,213,771.
- Cash and short-term investments at June 30, 2026: approximately $16.8 million (Cash $7,076,533; Short-term investments $9,761,994).
- Research and development expense for the quarter: $2,077,116, before recognizing $1,336,263 in collaboration credits.
- General and administrative expense for the quarter: $1,383,504.
Business Highlights
- Advanced enrollment in the Phase 2 ABACUS-2 trial for KIO-301, including initiation of the higher 100 µg dose cohort; an independent predefined safety review will follow treatment of initial higher-dose patients.
- Continued enrollment in the higher-dose cohort of the Phase 2 KLARITY trial for KIO-104, with initial clinical data expected in late 2026 to assess activity across inflammatory retinal conditions with macular edema.
- Collaboration structure: Théa Open Innovation is fully reimbursing KIO-301 development costs under their license for U.S., Europe and other select countries outside Asia; Senju holds options in Japan, China and select Asian territories.
- Secured a private placement for up to $24.0 million in gross proceeds, with $5.0 million received upfront and remaining proceeds contingent on exercise of milestone-based warrants; company said proceeds support operations and potential strategic activity.
- Management pursuing potential strategic transactions to diversify and expand the pipeline and preparing personnel and operating capabilities to move quickly if a transaction completes.
Original SEC Filing: KIORA PHARMACEUTICALS INC [ KPRX ] - 8-K - Aug. 07, 2026